LPTX vs AZN

Leap Therapeutics, Inc.

(LPTX) offers the better valuation at 11. 0x trailing P/E, making it the more compelling value choice. Analysts rate AstraZeneca PLC (AZN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Leap Therapeutics, Inc.

(LPTX) is the cheapest at 11. 0x versus AstraZeneca PLC at 28. 3x.

Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +87.

0%, compared to -95. 2% for Leap Therapeutics, Inc. (LPTX). Over 10 years, the gap is even starker: AZN returned +268. 6% versus LPTX's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AstraZeneca PLC (AZN) is the lower-risk stock at 0.

67β versus Leap Therapeutics, Inc. 's 2. 47β — meaning LPTX is approximately 269% more volatile than AZN relative to the S&P 500. On balance sheet safety, Leap Therapeutics, Inc. (LPTX) carries a lower debt/equity ratio of 0% versus 61% for AstraZeneca PLC — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190.

7% year-over-year, compared to 103. 9% for Leap Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Leap Therapeutics, Inc.

(LPTX) is the more profitable company, earning 73. 4% net margin versus 17. 5% for AstraZeneca PLC — meaning it keeps 73. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus -196. 5% for LPTX. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AZN (1.

8% yield) pays a dividend. LPTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +268. 6% 10Y return). Leap Therapeutics, Inc. (LPTX) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AZN: +268. 6%, LPTX: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LPTX is a small-cap deep-value stock; AZN is a large-cap quality compounder stock. AZN pays a dividend while LPTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.